🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT07121348
Active, not recruiting Not applicable

Effect of Different NanoScaffolds on Pulp Regeneration in Non-Vital Immature Permanent Teeth (Randomized Clinical Trial)

NCT07121348 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-07-28
Last updated
2025-08-13

Condition(s) studied

Necrotic Immature Permanent Incisors

Investigational drug(s) / intervention(s)

Platelet rich fibrin

Platelet rich fibrin: platelet rich fibrin is obtained by removing the middle layer from a centrifuged blood sample and is rich with platelets that plays an important role in tissue regeneration mesoporous silica nanoparticles are high surface area and excellent biocompatibility and enhance the outcome hyalurnic acid nanoparticles are high water capacity and involved in cell proliferation and adhesion and help in tissue regeneration pomegranate nanoparticles has anti-inflammatory and antibacterial effect and also help in tissue proliferation and regeneration

Study summary

the clinical trial aims to evaluate efficency of different scaffolds in cases of regeneration

Eligibility

Sex
ALL
Min age
9 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria:• Patients free from any systemic diseases that may interfer with the normal healing process. * Maxillary traumatized or cariously exposed non-vital immature anterior teeth. * Teeth don't need for post and core as a final restoration. * Radiographic evidence of an apical opening width more than 2 mm with or without periapical radiolucency. * Teeth without anatomical variations Exclusion Criteria:• Immunocompromised patients * Teeth with previous endodontic treatment. * Teeth with internal or external resorption * Radiographic evidence of root fracture. * Lack of patient and parent cooperation. * Presence of periodontal pocket depth more than 4 mm.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dentistry,Tanta University Tanta Gharbia Governorate

More Tanta University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07121348 on ClinicalTrials.gov ↗ ← All trials in Egypt